📰 Immaterial Misstatements News
Immaterial Misstatements News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immaterial Misstatements. Real-time updates on events, politics, business and more.
August 22, 2023
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfolio reprioritization and extension of cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody
August 22, 2023
(2023-08-22 | NDAQ:LVTX) LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
June 8, 2023
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The... | June 8, 2023
June 8, 2023
Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED... | June 8, 2023
September 13, 2022
13.09.2022 - Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth ...